Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + tislelizumab + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Based on the search results provided, this specific four-drug combination therapy involving fruquintinib, tislelizumab, capecitabine, and oxaliplatin is not documented. The search results discuss combinations of fruquintinib and tislelizumab, and separately capecitabine and oxaliplatin (CAPOX), but there is no information indicating that all four drugs are used together as a single, established treatment regimen or are currently being studied in this precise combination. Therefore, specific details about this exact four-drug combination cannot be provided based on the available search results.
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on fruquintinib + tislelizumab + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + tislelizumab + capecitabine + oxaliplatin.